Why Investors Need to Take Advantage of These 2 Finance Stocks Now

Zacks identifies CME Group and Prudential as potential earnings-beat candidates ahead of their next reports, based on positive Earnings ESPs: CME is +1.44% ($3.00 Most Accurate Estimate vs. $2.95 consensus) and Prudential is +0.96% ($3.48 vs. $3.44). CME has a Zacks Rank #3 (Hold) and reports October 21, 2026; Prudential has a #2 (Buy) rank and reports November 3, 2026. The article cites a Zacks backtest in which stocks with a #3-or-better rank and positive ESP produced positive surprises 70% of the time and averaged 28.3% annual returns over 10 years; neither company’s upcoming results are assured.

Analysis

The useful signal here is not the small positive estimate gap; it is whether revisions reflect improving underlying drivers. For CME, that means volume and product mix across rates, equity, energy and FX derivatives—not simply a one-quarter EPS beat. Elevated volatility can lift activity, but a return to calmer markets may quickly reverse the benefit. Intercontinental Exchange and Nasdaq are relevant read-throughs: if CME’s results point to broad exchange-volume strength, the implication extends beyond CME; if growth is product-specific, competitors may not share it.

For Prudential Financial, an EPS surprise is harder to underwrite from revisions alone. Investment spread income, credit experience, policyholder behavior and market-sensitive items can make reported earnings diverge from the quality or persistence of the beat. A positive print without stronger operating evidence may not support a durable rerating.

The article’s backtest is promotional evidence, not an investable edge by itself: it does not establish that these specific signals outperform after transaction costs, event moves, or selection effects. With no valuation, options-implied move, positioning, or estimate-revision history provided, the signal is mildly positive but insufficient for an outright pre-earnings bet. Near-term catalysts are the two reports; over 1–3 months, follow-through in guidance and operating metrics matters more than the headline beat. Structural implications are limited absent evidence that activity or insurance earnings trends are changing.

Key Decisions for Investors

• CME: avoid buying solely on the +1.44% estimate gap. Before the October 21 report, check options-implied move, recent estimate revisions, and positioning; consider a small, defined-risk event position only if the implied move is modest versus the historical post-report move and market-activity indicators support the estimate.
• After CME reports, favor a beat accompanied by resilient transaction volumes and constructive outlook over an EPS-only surprise. Falsifier: weaker forward activity commentary or a sharp normalization in volatility that undermines volume expectations.
• PRU: treat the +0.96% gap as a watch item, not a standalone long. On November 3, verify spread income, credit experience, policyholder behavior, and the composition of any earnings beat; a beat driven by volatile or non-recurring items would weaken the thesis.
• No CME–PRU pair is warranted from this evidence: their earnings drivers and report dates differ. Reassess only after comparing each report with its own options-implied move and operating indicators.